Xiangru Powder Veterinary Grade API is a dried, comminuted botanical active pharmaceutical ingredient prepared from the aerial parts of Mosla chinensis Maxim. or the cultivated Jiangxiangru chemotype. It is supplied as a brown to dark-brown powder with a characteristic thymol–carvacrol odour and is intended for further manufacture of tablets, capsules, oral powders, granules, premixes, oral solutions, and—after extraction and purification—injectable preparations. The term “API” here denotes a standardised multi-component powder rather than an isolated chemical entity; the veterinary activity is associated with the essential oil fraction, in which carvacrol, thymol, p-cymene, and γ-terpinene are the principal marker compounds. Commercial grade identifiers are supplier-specific and typically append the target sieve fraction to a botanical source code. Examples include XR-VET-80M for premix and granule operations and XR-VET-120M for tablet and capsule processing; a micronised XR-VET-200M may be offered where direct-compression flowability is controlled by external glidant addition. Representative release parameters include loss on drying ≤ 5.0% by USP <921>, total ash ≤ 12.0%, acid-insoluble ash ≤ 3.0%, heavy metals ≤ 20 mg/kg, arsenic ≤ 2 mg/kg, total aerobic microbial count ≤ 10⁴ CFU/g, and absence of Salmonella in 25 g by ISO 6579-1:2017. These values are representative of botanical powders for oral veterinary dosage forms and must be confirmed against the registered specification in the target market.

When Xiangru Powder Replaces Single-Entity Antimicrobial Agents in Oral Dosage Forms

Substitution of a synthetic single-entity active with Xiangru Powder alters formulation development because the matrix is heterogeneous and fibrous. Direct compression is generally confined to low-dose strengths; at higher loadings, the powder produces friable tablets and requires elevated compression forces. Pre-blending with microcrystalline cellulose and croscarmellose sodium is standard, followed by wet granulation with a 5–10% povidone solution when the dry blend exhibits an angle of repose above 40° measured by USP <1174>. Blend uniformity acceptance is assessed according to FDA Guidance for Industry: Powder Blends and Finished Dosage Units—Stratified Sampling, with marker RSD ≤ 5.0%. The wet mass is typically dried in a fluid-bed dryer with inlet air no higher than 55°C; processing above this threshold reduces total essential oil content through volatilisation of thymol and carvacrol. In a tray-drying operation, a drying endpoint of 3.0–5.0% moisture is recommended before lubrication and compression. Capsule filling of the 120M fraction is more robust when residual moisture is maintained below 7.0% to prevent dosator nozzle bridging, but published data for this specific configuration is limited and die-filling trials on the target encapsulation machine remain necessary.

Premix and granule production are less sensitive to compaction behaviour but more sensitive to segregation and carrier density differences. The 80M fraction is typically incorporated into a limestone or lactose carrier before dilution into complete feed. Bulk density, measured by USP <616> Method I, is the controlling variable for pneumatic conveying and silo discharge. Because the botanical powder is lower in bulk density than mineral carriers, stratification can occur in 1-tonne totes or farm-pack bags unless the carrier blend is density-adjusted or a post-blending granulation step is used. Dry granulation through a roller compactor with 0.8–1.2 mm screen sizing reduces dust and improves metering auger flow. The main batch-to-batch variance is not particle size but essential oil content; therefore, the incoming API should be pre-blended to the certificate-of-analysis marker value before addition to the production ribbon blender. In feed-mill operations, post-manufacture marker assay should be performed on composite samples collected at 10 defined points across the discharge stream to verify homogeneity.

What Limits Direct Use of Xiangru Powder in Injectable and Solution Formulations?

The powder is not directly dispersed into injectable vehicles. Injectable preparations require an upstream extraction stage: steam distillation or hydrodistillation of the dried aerial parts to recover the volatile fraction, or aqueous ethanol extraction followed by filtration. Direct suspension in water-for-injection is unsuitable because residual plant fibres and lipophilic essential oil droplets produce particulate load beyond the limits of USP <788>. Steam-distilled Xiangru oil is thermolabile; prolonged heating above 100°C shifts the marker profile through oxidation of γ-terpinene to p-cymene, so distillation time and condenser temperature are critical process parameters. The resulting oil is typically diluted in a non-aqueous vehicle or emulsified with 0.2–0.5% polysorbate 80 before aqueous dilution. For oral solutions, a filtered decoction through 10 µm or tighter cartridge filtration may be stabilised with 0.2–0.5% polysorbate 80 to maintain essential oil dispersion. Sterile filtration of decoction intended for injection requires compatibility testing with nylon or PVDF membranes; membrane binding of thymol and carvacrol varies with ethanol concentration and pH, and published data for this specific configuration is limited.

Residual moisture is a critical control across all dosage paths because the essential oil fraction undergoes oxidative degradation in humid storage. The powder is typically held at ≤ 60% relative humidity and processed within 30 days of sack opening. Re-drying in a forced-air tray dryer at 45–55°C may be performed before size reduction; higher temperatures volatilise thymol and carvacrol, reducing marker assay values. The powder should not be combined with strong oxidising agents or acidified premixes containing mineral acids, because acid-catalysed dehydration of the monoterpene fraction produces compositional drift. Adsorption onto hydrated carriers such as uncalcined bentonite may stabilise the essential oil in premixes, but carrier selection must be validated by headspace gas chromatography rather than visual inspection. Packaging for the API should include a heat-sealed aluminium foil laminate with desiccant, because high-density polyethylene alone does not provide an adequate moisture barrier for long-haul tropical storage.

Release Testing Parameters Distinguished from Crude Herbal Feed Powders

The tabulated parameters separate a veterinary-grade API from unstandardised crude botanical material.

Marker standardisation is performed by gas chromatography with flame ionisation detection or GC-MS, using carvacrol and thymol as the primary quantification peaks. The assay is not stability-indicating unless forced-degradation studies have demonstrated resolution of oxidation products such as p-cymene and thymoquinone from the parent peaks. For release testing, the essential oil is recovered by steam distillation from a 50 g sample before chromatographic analysis, following the distillation time specified in the supplier’s monograph. The ratio of thymol to carvacrol is often specified as a batch fingerprint; however, because the ratio shifts with drying temperature and storage duration, a specification expressed as total essential oil content plus a range for the ratio is more reproducible than a single marker limit.

Compared with synthetic veterinary antimicrobial powders such as enrofloxacin or doxycycline, Xiangru Powder does not possess a defined chemical purity or a single pharmacokinetic marker. The activity is mediated by a multi-component essential oil whose absorption and tissue distribution are not described by a single clearance model. Compared with crude herb powders sold as feed additives, the veterinary-grade API differs in controlled sieve fraction, loss on drying, heavy-metal limits, and microbial bioburden. The grade intended for injectable upstream processing requires additional pesticide residue screening per USP <561> and endotoxin control per USP <85> after extraction, because botanical matrices may contain pyrogenic material that would fail limit tests. No weight-to-weight substitution should be made between Xiangru Powder and isolated synthetic actives; each finished dosage form must be revalidated for marker content, dissolution, stability, and microbial quality.

Production-scale experience with botanical APIs of this type indicates that the principal bottleneck is not initial blending but the control of marker ratio during drying and storage. In a twin-shell blender, extended mixing beyond 15–20 minutes after lubrication can cause electrostatic coating of the botanical particles by magnesium stearate, which retards dissolution of the essential oil markers. On rotary tablet presses, dies heated by prolonged compression above 45°C may volatilise surface oil and produce oily residues on punch faces, requiring periodic wiping with food-grade ethanol. In high-shear granulation, the impeller speed should be limited to 200–300 rpm for the pre-granulation blend because excessive shear ruptures glandular trichomes and exposes the essential oil prematurely. These process boundaries are derived from equipment-scale observations in botanical processing lines and should be confirmed with the specific equipment train before commercial batches are released.